Cardiac resynchronisation therapy (CRT) could benefit more than a million heart failure patients worldwide who are not currently considered eligible for the treatment. Initial results from a retrospective analysis of data from the postmarket PROSPECT study, sponsored by Medtronic, ...
Please Login to read the full article.
